Strand Life Sciences, India, has announced that the company has joined the Global Diagnostics Network (GDN), a strategic working group of major diagnostic laboratories collaborating to generate enhanced diagnostics insights to improve the delivery of global healthcare.

 

The GDN, launched in October 2018 by U.S.-basedQuest Diagnostics, consists of the following companies:Al Borg Medical Laboratories,Dasa,GC Labs,Healius,KingMed Diagnostics, andSYNLAB. It is believed that LSI Mediencealso joined the GDN on the same day as Strand.

 

Strand says that the GDN initiatives will benefit patients, healthcare providers, pharmaceutical innovators, government agencies, non-governmental organizations (NGOs), and academic institutions. Starting priority areas of focus include the standardized delivery and development of high-quality companion diagnostics for pharmaceutical companies, and the creation of an emerging pathogen preparedness network to expedite infectious disease research and response. Additional initiatives will be rolled out based on regional and global priorities.

 

In India, Strand Life Sciences is focused on Oncology, Mother and Child, and technology-enabled Wellness segments. “We are very pleased to join the GDN and learn from the rich experience of our fellow members as well as contribute through our special capabilities in genetics, bioinformatics and oncology,” said Harish Natarajan, Chief Operating Officer and President, Clinical Diagnostics at Strand Life Sciences.

The GDN, powered by U.S. based Quest Diagnostics, brings together leaders in diagnostics information services to share expertise and drive innovation